Caricamento...

Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers

In treating cancer with clinically approved chemotherapies, the high systemic toxicity and lack of selectivity for malignant cells often result in an overall poor response rate. One pharmacological approach to improve patient response is to design targeted therapies that exploit the cancer milieu by...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Vielhauer, George A., Swink, Megan, Parelkar, Nikhil K., Lajiness, James P., Wolfe, Amanda L., Boger, Dale
Natura: Artigo
Lingua:Inglês
Pubblicazione: Landes Bioscience 2013
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813569/
https://ncbi.nlm.nih.gov/pubmed/23760495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24348
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !